Skip to main content

Advertisement

SpringerLink
Log in

Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport®) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objective

To assess the effects of two different doses of botulinum toxin A (Dysport®: 500 and 1,000 IU) injected repeatedly into the bladder for the treatment of neurogenic detrusor overactivity (NDO) in terms of safety, durability, and improvement of continence status and urodynamic parameters.

Patients and methods

In this study we analyzed the effects of successive doses of 500 or 1,000 IU of Dysport®, endoscopically injected into the detrusor muscle. Clinical, urodynamic, and satisfaction assessments were performed at baseline and 6 weeks after each injection. The results of injections and corresponding follow-ups were analyzed and compared with baseline.

Results

Twenty-two patients (13 men and 9 women) with repeated four injections were included, of whom 12 (55%) with mean age 35.7 years (range 16–52 years) received 500 IU of BTX-A and 10 (45%) with mean age 33.8 years (range 18–50 years) received 1,000 IU in each treatment. No statistically significant differences were found in efficacy duration with the two Dysport doses (500 IU: 7.7 months, 1,000 IU: 8.5 months; P > 0.05). Maximum cystometric capacity (MCC), reflex volume (RV), and bladder compliance (BC), and patient satisfaction improved significantly after each treatment compared with baseline values and there were no statistically significant differences after each retreatment for the two treatment groups (P > 0.05).

Conclusions

After repeated injections the effect of BTX-A remained constant. The cause of repeat treatment is relapse of overactive bladder symptoms. Results with the 500 and 1,000 IU doses were interesting and approximately equivalent in terms of duration and efficacy, with better but not significant results when 1,000 IU was used. The optimum dose of Dysport for incontinence secondary to NDO is not yet defined; 1,000 IU probably has a nonsignificant longer effect than 500 IU but may expose the patient to major complications. Further studies evaluating the clinical efficacy of 750 IU of Dysport are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44:165–174. doi:10.1016/S0302-2838(03)00250-1

    Article  CAS  PubMed  Google Scholar 

  2. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177–185. doi:10.1016/S0022-5347(06)00590-8

    Article  CAS  PubMed  Google Scholar 

  3. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) Comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989. doi:10.1097/01.ju.0000169480.43557.31

    Article  CAS  PubMed  Google Scholar 

  4. Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26:531–536. doi:10.1002/nau.20403

    Article  CAS  PubMed  Google Scholar 

  5. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704–709. doi:10.1016/j.eururo.2005.12.002

    Article  CAS  PubMed  Google Scholar 

  6. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CG, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535. doi:10.1016/j.eururo.2005.12.012

    Article  PubMed  Google Scholar 

  7. Patki PS, Hamid R, Arumugam K, Shah PJR, Craggs M (2006) Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98:77–82. doi:10.1111/j.1464-410X.2006.06192.x

    Article  CAS  PubMed  Google Scholar 

  8. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653–659. doi:10.1016/j.eururo.2004.11.009

    Article  CAS  PubMed  Google Scholar 

  9. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030–1034. doi:10.1111/j.1464-410X.2006.06091.x

    Article  CAS  PubMed  Google Scholar 

  10. Odergren T, Hjaltason H, Kaakkola S et al (1998) A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64:6–12. doi:10.1136/jnnp.64.1.6

    Article  CAS  PubMed  Google Scholar 

  11. Schäfer W, Abrams P, Liao L et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261–274. doi:10.1002/nau.10066

    Article  PubMed  Google Scholar 

  12. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697. doi:10.1016/S0022-5347(05)67283-7

    Article  CAS  PubMed  Google Scholar 

  13. Barinaga M (1993) Secrets of secretion revealed. Science 260:487–489. doi:10.1126/science.8475382

    Article  CAS  PubMed  Google Scholar 

  14. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E (2006) Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058–1064. doi:10.1016/j.eururo.2006.01.025

    Article  PubMed  Google Scholar 

  15. Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200. doi:10.1097/01.ju.0000162035.73977.1c

    Article  CAS  PubMed  Google Scholar 

  16. Grosse J, Kramer G, Tong TQT, Stohrer M, Jakse G (2005) Efficacy, dosage and safety of Dysport English botulinum toxin A in severe neurogenic detrusor overactivity NDO. Eur Urol Suppl 4:405

    Google Scholar 

  17. Del Popolo G, Filocamo MT, Marzi VL et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 53:1013–1020. doi:10.1016/j.eururo.2007.09.034

    Article  CAS  PubMed  Google Scholar 

  18. Holds JB, Alderson K, Fogg SG, Anderson RL (1990) Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci 31:964–967

    CAS  PubMed  Google Scholar 

  19. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029. doi:10.1016/S0022-5347(01)66376-6

    Article  CAS  PubMed  Google Scholar 

  20. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515. doi:10.1016/j.eururo.2003.12.004

    Article  CAS  PubMed  Google Scholar 

  21. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E (2007) Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52:1729–1735. doi:10.1016/j.eururo.2007.08.052

    Article  PubMed  Google Scholar 

  22. Haferkamp A, Schurch B, Reitz A et al (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46:784–791. doi:10.1016/j.eururo.2004.07.011

    Article  CAS  PubMed  Google Scholar 

  23. Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977–982. doi:10.1097/01.ju.0000169481.42259.54 discussion 982–983

    Article  CAS  PubMed  Google Scholar 

  24. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644–650. doi:10.1016/j.eururo.2005.12.010

    Article  CAS  PubMed  Google Scholar 

  25. Borodic GE, Ferrante R (1992) Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 12:121–127

    CAS  PubMed  Google Scholar 

  26. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193–1197. doi:10.1016/j.urology.2006.08.1069

    Article  PubMed  Google Scholar 

  27. Giannantoni A, Mearini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79–87

    CAS  PubMed  Google Scholar 

  28. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH (2003) Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139–143. doi:10.1016/S0302-2838(03)00136-2

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Jordan University of Science & Technology, King Abdullah University Hospital, P.O. Box 940165, Irbid, Amman, 11194, Jordan

    Ibrahim Fathi Ghalayini, Mohammed A. Al-Ghazo & Ziad Ali Elnasser

Authors
  1. Ibrahim Fathi Ghalayini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed A. Al-Ghazo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziad Ali Elnasser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim Fathi Ghalayini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghalayini, I.F., Al-Ghazo, M.A. & Elnasser, Z.A. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport®) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. Int Urol Nephrol 41, 805–813 (2009). https://doi.org/10.1007/s11255-009-9528-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-009-9528-y

Keywords

Search

Navigation